Deepti Behl
About
Deepti Behl is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Deepti Behl has authored 29 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Deepti Behl's work include Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Advanced Breast Cancer Therapies (3 papers). Deepti Behl is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Advanced Breast Cancer Therapies (3 papers). Deepti Behl collaborates with scholars based in United States. Deepti Behl's co-authors include Paul Mehan, Jeremy Kortmansky, Ramesh K. Ramanathan, Katherine A. Guthrie, E. Gabriela Chiorean, Rakesh Gaur, Tara Elisabeth Seery, Jill Lacy, Sunil R. Hingorani and Shannon McDonough and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and CHEST Journal.
In The Last Decade
Deepti Behl
27 papers receiving 593 citations
Peers
Deepti Behl
Monika Csóka Hungary
Suneel D. Kamath United States
Hwa Jung Sung South Korea
Kayoko Kibata Japan
Dominic W. Lai United States
Cyrus Sayehli Germany
P H de Mulder Netherlands
Chun‐Hsin Wu Taiwan
Min Sung An South Korea
Julien Lazarovici France
Citations per year, relative to Deepti Behl Deepti Behl (= 1×)
peers
Monika Csóka
Countries citing papers authored by Deepti Behl
Since
Specialization
Citations
This map shows the geographic impact of Deepti Behl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deepti Behl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deepti Behl more than expected).
Fields of papers citing papers by Deepti Behl
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Deepti Behl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deepti Behl. The network helps show where Deepti Behl may publish in the future.
Co-authorship network of co-authors of Deepti Behl
This figure shows the co-authorship network connecting the top 25 collaborators of Deepti Behl. A scholar is included among the top collaborators of Deepti Behl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deepti Behl. Deepti Behl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schuetze, Scott M., Michael Rothe, Pam K. Mangat, et al.. (2024). Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 8(8). e2400219–e2400219.
2.
Levi, Jelena, Millie Das, Deepti Behl, et al.. (2024). [18F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non–Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. Journal of Nuclear Medicine. 65(12). jnumed.124.268253–jnumed.124.268253.
3.
Mileham, Kathryn F., Michael Rothe, Pam K. Mangat, et al.. (2023). Abstract CT226: Crizotinib (C) in patients (pts) with solid tumors with MET amplification (amp) or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT226–CT226.
4.
Ganti, Apar Kishor, Michael Rothe, Pam K. Mangat, et al.. (2023). Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology. 7(7). e2300041–e2300041.
5.
Khalil, M.F., Michael Rothe, Pam K. Mangat, et al.. (2023). 207P Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. 34. S265–S266.
6.
Rothe, Michael, Pam K. Mangat, Elizabeth Garrett‐Mayer, et al.. (2023). Abstract CT231: Temsirolimus (T) in patients (pts) with solid tumors with PTEN mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Cancer Research. 83(8_Supplement). CT231–CT231.
7.
Kütük, Tuğçe, Joshua M. Walker, Matthew T. Ballo, et al.. (2023). Multi-Institutional Patterns of Use of Tumor-Treating Fields for Patients with Malignant Pleural Mesothelioma. Current Oncology. 30(6). 5195–5200.
8.
Cannon, Timothy Lewis, Michael Rothe, Elizabeth Garrett‐Mayer, et al.. (2023). Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(4_suppl). 546–546.
9.
Behl, Deepti, Michael Rothe, Pam K. Mangat, et al.. (2023). Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(4_suppl). 122–122.
10.
Drescher, Charles W., Michael Rothe, Pam K. Mangat, et al.. (2023). Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 5548–5548.
11.
Calfa, Carmen, Michael Rothe, Gordan Srkalović, et al.. (2023). Temsirolimus (T) in patients (pts) with solid tumors with PIK3CA mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. 41(16_suppl). 3117–3117.
12.
Mangat, Pam K., Elizabeth Garrett‐Mayer, Elie G. Dib, et al.. (2022). 978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Annals of Oncology. 33. S997–S998.
13.
Ramanathan, Ramesh K., Shannon McDonough, Philip Agop Philip, et al.. (2018). A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139).. Journal of Clinical Oncology. 36(4_suppl). 208–208.
14.
Schild, Steven E., Deepti Behl, Svetomir N. Markovic, et al.. (2010). Brain Metastases From Melanoma. American Journal of Clinical Oncology. 33(6). 633–636.
15.
Behl, Deepti, Andrea Wahner Hendrickson, & Timothy J. Moynihan. (2009). Oncologic Emergencies. Critical Care Clinics. 26(1). 181–205.
16.
Behl, Deepti, Kay M. Ristow, Svetomir N. Markovic, et al.. (2007). Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. British Journal of Haematology. 137(5). 409–415.
17.
Behl, Deepti & Aminah Jatoi. (2007). Pharmacological options for advanced cancer patients with loss of appetite and weight. Expert Opinion on Pharmacotherapy. 8(8). 1085–1090.
18.
Khan, Syed Anjum, et al.. (2007). Outcome of Patients With Small-Vessel Vasculitis Admitted to a Medical ICU. CHEST Journal. 131(4). 972–976.
19.
Behl, Deepti, et al.. (2005). Sepsis and Myocardial Depression in a Young Woman. Mayo Clinic Proceedings. 80(6). 810–814.
20.
Behl, Deepti, L.F. Porrata, Svetomir N. Markovic, et al.. (2005). Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia. 20(1). 29–34.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Monika Csóka Breakdown of academic impact, for papers by Suneel D. Kamath Breakdown of academic impact, for papers by Hwa Jung Sung Breakdown of academic impact, for papers by Kayoko Kibata Breakdown of academic impact, for papers by Dominic W. Lai Breakdown of academic impact, for papers by Cyrus Sayehli Breakdown of academic impact, for papers by P H de Mulder Breakdown of academic impact, for papers by Chun‐Hsin Wu Breakdown of academic impact, for papers by Min Sung An Breakdown of academic impact, for papers by Julien Lazarovici